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abstract
NewWHOguidelinesformeaslesoutbreakresponseinmeaslesmortalityreductionsettings
nowincludereactivevaccinationforoutbreaks.Hereweusedsurveillancedataandvaccine
coverage surveys following two mass vaccine campaigns in the Democratic Republic of
Congo, to show the impact of reactive vaccination on reducing cases during outbreaks.
The number of measles cases reported was collected via the national surveillance sys-
tem. Following vaccination campaigns, two-stage cluster sampling surveys were used to
evaluate pre and post campaign coverage.
In Matadi, 1035 cases were reported from 24 October 2005 to 19 February 2006 and in
Mbuji Mayi, 4734 cases were reported from 3 October 2005 to 30 April 2006. Following
the mass vaccination campaign, coverage rose from 87.5% (95% CI 87.2–87.8) to 97.1% (95%
CI 96.9–97.3) in Matadi and from 74.0% (95% CI 70.9–77.0) to 96.5% (95% CI: 95.7–97.2) in
Mbuji Mayi. Weekly reported cases reduced respectively by 89.3% and 68.9% in the 3 weeks
following the mass vaccination campaigns.
The introduction of reactive vaccination for measles outbreak control provides an addi-
tional tool to help reduce the impact of outbreaks. Our experience shows that this type of
intervention is feasible and effective even when baseline vaccination coverage is>70%.
© 2010 Royal Society of Tropical Medicine and Hygiene. Published by Elsevier Ltd. All
rights reserved.
1. Introduction
The Democratic Republic of Congo (DRC) is a vast coun-
try with 65 million inhabitants. It has poor transport
infrastructure,withrunningwaterandelectricityonlypar-
tially available in urban centres. These difﬁculties, linked
with limited human resources, make ensuring high rou-
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tine vaccination coverage (VC) challenging and measles
outbreaks are regularly reported.
Measles cases in DRC are reported to the Ministry of
Health (MoH) through a national surveillance network of
healthstructures.AttheendofOctober2005,thenumberof
reportedmeaslescasesbegantoriseinthewesterntownof
Matadi (population 204000, MoH 2005). The last outbreak
in this area occurred in 2002–2003 with over 1000 cases
reported during six months. No supplementary wide-age
range (age 6 months to 15 years) mass vaccination cam-
paigns (MVC) had been carried out in recent years. As cases
1876-3413/$ – see front matter © 2010 Royal Society of Tropical Medicine and Hygiene. Published by Elsevier Ltd. All rights reserved.
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continued to rise, Médecins Sans Frontières (MSF), a non-
governmental organization, in partnership with the MoH,
implementedaMVCforchildrenaged6monthsto15years
during the ﬁrst week of January 2006. This campaign was
conducted as part of control efforts, which included rein-
forcing surveillance and providing treatment for measles
patients free of charge.
When a simultaneous outbreak erupted in the central
Congolese city of Mbuji Mayi (population 2.3 million), the
MoH and MSF provided the same package of surveillance,
free access to treatment and a MVC in an effort to control
the outbreak. This time only children aged 6 months to 5
years were targeted during the MVC as a supplementary
wide-age range campaign had been carried out in Mbuji
Mayi in December 2002 (reported coverage 96.4%), and for
logistic reasons. Both outbreaks were conﬁrmed by labora-
tory testing carried out under the supervision of the WHO
in DRC.
The primary objective of the MVCs was to control
the outbreak and reduce measles morbidity. We present
surveillance data and the results of VC surveys conducted
after the MVCs to document whether they were effective
control measures in reducing measles cases.
2. Methods
In Matadi, surveillance data was collected from 1 June
(Week 22), 2005 to 19 February (Week 7) 2006 from
the registers of all 39 outpatient public health structures.
In Mbuji Mayi, surveillance data was collected from 19
September (Week 38) 2005 to 30 April (Week 17) 2006
from137ofthe411outpatienthealthstructures.These137
centres were the most visited, and had received 70% of all
measles cases reported to the end of February 2006. Data
was collected for patients resident in Matadi and Mbuji
Mayi, the target areas for the MVCs. Inpatient data was not
included to avoid double-counting, as inpatients must be
referred from an outpatient structure. We used the MoH
casedeﬁnitionofsuspectedmeasles:anypersonwithfever
and maculopapular rash and cough, coryza or conjunctivi-
tis. Data presented is for children aged 0 to 14 years.
In Matadi, 25 vaccination sites were used and the MVC
carried out over four days. In the larger city of Mbuji
Mayi, the MVC was carried out sequentially in three pre-
deﬁned geographic areas, using over 100 vaccination sites.
Social mobilisation to promote the MVCs was conducted
prior to vaccination in both sites. The campaigns were
conducted according to MSF standard organisation of vac-
cination sites.1
The VC in both cities was evaluated using two-stage
cluster sampling surveys.2 Population lists of administra-
tive sub-units were used to select clusters proportional to
population size. A sample size of 24 children in each of 30
clusters was calculated for a precision of ±2.5% based on
65% coverage.2 Households were selected using the spin-
the-pen method described previously.3
After providing oral informed consent, information was
collected from the head of household on age, gender,
measlesvaccinationstatuspreandpostcampaign,andrea-
son for non-vaccination if applicable for children in the
target group. If no vaccination card was presented, the
interviewersaskedwherethechildwasvaccinated.InDRC,
measles vaccine is the only vaccine administered in the left
arm. Data on the number of times a child was vaccinated
for measles was also recorded.
Data was entered into EpiData (Odense, Denmark) and
analysed in Stata 9.0 (College Station, Texas, USA). Follow-
ing data entry, one child per household was selected at
random for inclusion in the analysis. Authorization was
obtained for these surveys from the Ministry of Health.
3. Results
Between Week 43 2005 and Week 6 2006, 1035 cases
of measles were reported in Matadi, an overall attack rate
(AR) of 0.5%. The AR was 2.1% in children under ﬁve and
0.4% in children from 5 to 14 years. The peak of 159 cases
was recorded in Week 1 2006, the week of the MVC, during
which 104839 children aged between 6 months and 15
years were vaccinated. There was a slight decrease to 135
cases (15.1%) during the two following weeks and then a
sharp decrease to 17 cases in Week 4; a reduction of 89.3%
from the week of the MVC (Figure 1).
The VC survey was carried out during Week 4 2006.
Prior to the MVC, the estimated coverage was 32.6% (95%
CI 31.9–33.4) by card or 87.5% (87.2–87.8) by card or oral
history. Following the MVC, the VC increased to 79.8%
(79.3–80.4) by card or 97.1% (96.9–97.3) by card or oral
history. Of the 579 children aged 12 to 59 months included
in the survey who reported, by card or oral history, to be
vaccinated during the MVC, 8.5% received their ﬁrst dose
(n=49) and 89.5% received a second dose (n=518) during
the MVC. Prior vaccination status was unknown for 2.1%
(n=12).
In Mbuji Mayi, from Week 40 2005 to Week 17 2006,
4734 cases of measles were reported, an overall AR of 0.3%.
The AR was 1.4% in children under 5 and 0.02% in children
5 to 14 years. A peak of 640 cases was reported in Week 11,
theweektheMVCbegan.Intotal359318childrenbetween
6 and 59 months were vaccinated in 11 days. The number
of cases decreased slightly to 540 (15.6%) the following 2
weeks and then decreased sharply to 199 cases in Week
14; a total decrease of 68.9% from the week of the MVC
(Figure 2).
Figure 1. Reported measles cases Week 28 2005 – Week 7 2006, Matadi,
Democratic Republic of Congo. The mass vaccination campaign was car-
ried out in Week 1, 2006.Author's personal copy
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Figure 2. Reported measles cases Week 41 2005–Week 16 2006, Mbuji
Mayi, Democratic Republic of Congo. The mass vaccination campaign was
carried out in Weeks 11 and 12.
The VC survey was carried out during Week 14 2008.
Prior to the campaign, the estimated coverage for measles
for Mbuji Mayi was 17.4% (13.2–21.5) by card or 74.0%
(70.9–77.0) by card or oral history. Following the cam-
paign, the coverage increased to 65.5% (61.9–69.0) by
card or 96.5% (95.7–97.2) by card or oral history. Of the
2005 children aged 12 to 59 months included in the sur-
vey who reported to be vaccinated during the campaign,
31.2%reportedreceivingtheirﬁrstdose(n=625)and60.0%
(n=1202) their second dose of vaccine. The remaining 8.2%
(n=165) reported receiving a third dose during the MVC.
Prior vaccination status was unknown for 0.6% (n=13).
4. Discussion
As recommended in new WHO guidelines for out-
break control in measles mortality reduction settings,4
non-selective MVCs were used effectively as a part of the
outbreak control strategy in the two outbreaks described
here. Routine vaccination against measles is available in
DRC, but our survey results show that the coverage was
insufﬁcient to prevent these outbreaks.
The surveillance data in both cities suggests that the
reactive campaign had a positive impact on the outbreak
curve. The number of cases decreased by 89% and 69% in
Matadi and Mbuji Mayi respectively, three weeks after the
mass vaccination campaign. This delay is expected as pro-
tection is only accorded 7 to 10 days post vaccination;
surveillance data is reported on a weekly basis and vac-
cination will not prevent children infected with measles
prior to vaccination from developing the disease. Previous
studies have shown the impact of reactive campaigns on
an outbreak where the baseline VC was low,5 our expe-
rience shows a positive impact in outbreaks where the
baseline VC was >70%. In addition, the surveillance data
priortoandfollowingtheMVCswereconsideredrepresen-
tative of the true measles outbreak epidemiology as good
public awareness campaigns about the free treatment of
measles cases had been carried out early on during each
outbreak.
Our results also show the beneﬁts of MVCs in provid-
ing opportunities for children to receive their ﬁrst dose
of measles vaccine, but also providing children with the
opportunity to receive their second dose as recommended
by WHO and UNICEF.6 An opportunity for a second dose is
not currently implemented within the DRC routine vacci-
nation programme.
It is also important to take into consideration the
resources necessary to implement this type of campaign
during an outbreak. Matadi is a small, contained city, and it
waslogisticallypossibletorapidlyorganizeaMVC.Inthese
conditions, it was possible to vaccinate over 100000 chil-
dren in 4 days. In contrast, Mbuji Mayi is a larger city and
spread over a much wider geographic area. The MVC was
resource intensive, with over 100 vaccination sites used to
vaccinate approximately 350000 children in 11 days.
Further, the campaigns were conducted at the time
of the apparent peak of cases in both cities. Although
the surveillance systems were sufﬁcient to detect the
increasing number of cases, logistical concerns meant that
the campaigns were delayed (for example, the Christ-
mas holiday). In addition, delays associated with the
implementation of large-scale policy changes following
modiﬁcation of WHO international recommendations are
to be expected. Had the MVCs been implemented earlier
during the outbreaks, their impact would probably have
been even greater.
Ultimately, achieving sufﬁciently high VC to prevent
outbreaks through routine vaccination is the best method
to prevent measles outbreaks and the resulting childhood
mortality. In DRC, large-scale reinforcement of the routine
immunization programme in terms of the number of chil-
drenvaccinatedandtheroutineadministrationofasecond
dose would be necessary to achieve this goal. An addi-
tional means of preventing outbreaks could be lowering
the minimum age of routine measles vaccination, which
would protect younger children and slow the accumula-
tion of the vulnerable population. Initial research on this
subject is yielding interesting results.7
Until this ultimate goal is achieved, our experience
shows that reactive vaccination in measles mortality
reduction settings like DRC, as recommended in the new
WHO guideline,4 is an effective way to reduce the scope
anddurationofmeaslesoutbreaks.Thereactivecampaigns
were effective even in settings where baseline coverage
is estimated at >70%. In all settings, good surveillance is
essentialtodetectanoutbreakandplanappropriateaction.
The feasibility of such an intervention will depend on
resources available and in some settings, outside resources
may be necessary to support this type of activity.
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